Athenex Announces Exclusive License Agreement With National Cancer Institute To Utilize T Cell Receptors Targeting Mutated p53, KRAS, And EGFR For The Development Of Autologous And Allogeneic Cell Therapies

by | Nov 9, 2021 | Uncategorized | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.